Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2024 · 49 positions · Total reported value $2.14B · Top-10 concentration 62.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 22.7% · 6 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2024 13F filing, Frazier Life Sciences Management, L.P. disclosed 49 equity positions with a combined reported value of $2.14B. The filing implies a focused portfolio: its ten largest positions account for 62.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2024 were NAMS ($234.88M), MIRM ($222.08M), KRYS ($181.52M). By sector, the heaviest allocations are Health Care 83.3%, Materials 0.2%. Versus the prior quarter, allocation shifted toward Health Care (+9.8pp) and away from Other (-9.7pp).

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 74% of names.

The largest new positions opened in Q2 2024 were ERAS ($38.27M), RARE ($17.47M), MREO ($15.84M).

Of the 3 positions fully exited versus the prior quarter, the largest were ALPN ($124.11M), APLS ($52.03M), AVTE ($35.63M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • ERAS ERASCA INC · $38.27M
  • RARE ULTRAGENYX PHARMACEUTICAL IN · $17.47M
  • MREO MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS · $15.84M
  • IMTX IMMATICS N.V · $13.39M
  • ELEV ELEVATION ONCOLOGY INC · $7.99M
  • DSGN DESIGN THERAPEUTICS INC · $4.00M
  • IMCR IMMUNOCORE HOLDINGS PLC-ADR COMP · $3.69M

Fully Exited (vs previous quarter)

  • ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $124.11M
  • APLS APELLIS PHARMACEUTICALS INC · prev qtr: $52.03M
  • AVTE AEROVATE THERAPEUTICS INC · prev qtr: $35.63M
  • GPCR STRUCTURE THERAPEUTICS INC · prev qtr: $26.97M
  • DCPH DECIPHERA PHARMACEUTICALS IN · prev qtr: $22.90M
  • NTLA INTELLIA THERAPEUTICS INC · prev qtr: $5.60M
  • GRTSQ GRITSTONE BIO INC · prev qtr: $2.65M
  • BLUE BLUEBIRD BIO INC · prev qtr: $2.19M

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 41 positions · $4.59B reported value (Q2 2026)
  • Top 10 holdings = 73.6% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
  • Average position size: $112.00M

Sector Tilt

  • Health Care 99.8%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
  • 26 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 83.3%
Materials 0.2%
Other 16.5%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 12.23M $234.88M 10.99%
10.99%
Hold
2 6.50M $222.08M 10.39%
10.39%
Hold
3 988.46K $181.52M 8.49%
8.49%
Hold
4 10.62M $153.52M 7.18%
7.18%
Add
5 10.11M $104.13M 4.87%
4.87%
Hold
6 2.37M $97.37M 4.55%
4.55%
Add
7 3.63M $92.01M 4.30%
4.30%
Add
8 8.79M $81.70M 3.82%
3.82%
Hold
9 1.75M $79.09M 3.70%
3.70%
Add
10 1.04M $78.49M 3.67%
3.67%
Reduce
11 3.73M $67.20M 3.14%
3.14%
Add
12 2.17M $54.27M 2.54%
2.54%
Add
13 3.31M $47.93M 2.24%
2.24%
Add
14 3.69M $43.44M 2.03%
2.03%
Hold
15 1.59M $43.15M 2.02%
2.02%
Reduce
16 997.46K $38.71M 1.81%
1.81%
Hold
17 16.22M $38.27M 1.79%
1.79%
New
18 871.97K $37.60M 1.76%
1.76%
Add
19 875.67K $35.73M 1.67%
1.67%
Hold
20 1.56M $33.61M 1.57%
1.57%
Hold
21 8.16M $32.87M 1.54%
1.54%
Add
22 4.14M $29.29M 1.37%
1.37%
Hold
23 770.00K $24.31M 1.14%
1.14%
Hold
24 1.50M $23.98M 1.12%
1.12%
Hold
25 373.10K $22.08M 1.03%
1.03%
Reduce
26 7.38M $22.00M 1.03%
1.03%
Hold
27 1.15M $21.82M 1.02%
1.02%
Hold
28 425.00K $17.47M 0.82%
0.82%
New
29 4.62M $16.09M 0.75%
0.75%
Hold
30 393.00K $16.07M 0.75%
0.75%
Hold
31 4.40M $15.84M 0.74%
0.74%
New
32 1.15M $13.39M 0.63%
0.63%
New
33 832.22K $13.31M 0.62%
0.62%
Hold
34 3.01M $12.80M 0.60%
0.60%
Add
35 2.29M $10.68M 0.50%
0.50%
Add
36 3.06M $9.98M 0.47%
0.47%
Add
37 1.00M $8.01M 0.38%
0.38%
Hold
38 2.96M $7.99M 0.37%
0.37%
New
39 936.58K $7.90M 0.37%
0.37%
Hold
40 470.34K $7.64M 0.36%
0.36%
Hold
41 285.33K $7.60M 0.35%
0.35%
Hold
42 1.07M $7.34M 0.34%
0.34%
Hold
43 2.87M $6.68M 0.31%
0.31%
Hold
44 2.09M $4.49M 0.21%
0.21%
Add
45 500.33K $4.36M 0.20%
0.20%
Hold
46 1.20M $4.00M 0.19%
0.19%
New
47 108.76K $3.69M 0.17%
0.17%
New
48 245.69K $1.00M 0.05%
0.05%
Reduce
49 264.38K $290.81K 0.01%
0.01%
Hold

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2024-Q2?

In its 2024-Q2 13F filing, Frazier Life Sciences Management, L.P. reported 49 equity positions worth $2.14B in aggregate; its largest disclosed positions were NAMS ($234.88M), MIRM ($222.08M), KRYS ($181.52M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $2.14B of long equity holdings across 49 positions as of 2024-Q2. Top-10 holdings account for 62.0% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →